The FDA cleared the IND application for ZW251, a product of Zymeworks.
4 reports, 1 independent
Updated Aug 25
Gone quiet
- Reports
- 4
- Developments
- 2
- Repetition
- 75%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
The FDA cleared the IND application for ZW251, a product of Zymeworks.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- Zymeworks achieved FDA approval for its drug zanidatamab, while also announcing personnel and award news.Sub-event
FDA cleared the IND application for ZW251.1 source
Keep exploring
The entities involved
Related events
Coverage
Newest first; wire copies grouped- GlobeNewswireZymeworks Provides Corporate Update and Reports Second Quarter 2025 Financial Results Investigational new drug (IND) application cleared by the United States Food and Drug Administration (FDA) for ZW
- GlobeNewswireZymeworks Announces FDA Clearance of Investigational New Drug Application for ZW251, a Novel Glypican 3-Targeted Topoisomerase 1 Inhibitor Antibody-Drug Conjugate Second antibody-drug conjugate (ADC)